CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

被引：0

作者：

Chen Li-Tzong ^{[1
]}

Andrea, Wang-Gillam ^{[2
]}

Shan Yan-Shen ^{[3
]}

Teresa, Macarulla ^{[4
]}

Jean-Frederic, Blanc ^{[5
]}

Richard, Hubner ^{[6
]}

Chiu Chang-Fang ^{[7
]}

Gilberto, Schwartsmann ^{[8
]}

Jens, Siveke ^{[9
]}

Marc, Pipas J. ^{[10
]}

Bruce, Belanger ^{[10
]}

Floris, de Jong ^{[11
]}

Khalid, Mamlouk ^{[10
]}

Daniel, Von Hoff ^{[12
]}

机构：

[1] Natl Inst Canc Res, NHRI, Tainan, Taiwan

[2] Washington Univ, St Louis, MO USA

[3] Natl Cheng Kung Univ, Inst Clin Med, Tainan, Taiwan

[4] Vall dHebron Inst Oncol, Barcelona, Spain

[5] Hop Haut Leveque, Bordeaux, France

[6] Christie NHS Fdn Trust, Manchester, Lancs, England

[7] China Med Univ Hosp, Taichung, Taiwan

[8] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil

[9] Univ Hosp Essen, West German Canc Ctr, Essen, Germany

[10] Merrimack Pharmaceut Inc, Cambridge, MA USA

[11] Shire GmbH, Glattpk Opfikon, Switzerland

[12] TGen & HonorHlth, Phoenix, AZ USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PD - 017

引用

页数：2